Immortal Dragons backs Renewal Bio's donor-free cell platform
What's the deal? Immortal DragonsDealroom has a profile for this one. Try Dealroom →, a $40 million longevity fund based in Singapore, has led an early-stage investment in Renewal BioDealroom has a profile for this one. Try Dealroom →, an Israeli regenerative medicine company developing patient-matched human cells for transplantation. The company, founded in 2022, is a spinout of the Weizmann Institute of ScienceDealroom has a profile for this one. Try Dealroom →.
What's the endgame? Renewal Bio wants to remove the need for donor matches in cell transplants. Most transplantable cells come from donors today, leaving patients — such as those needing bone marrow transplants — to find immune-compatible matches and face rejection risks and long-term immunosuppression.
How it works: Its Stembroid platform reprograms ordinary skin or blood cells into stem cells, then lets those cells self-organise into a 3D model of early human development, without sperm or eggs. Target cell types emerge through natural developmental cues rather than chemical instructions in a dish.
The technology comes from the laboratory of Professor Jacob Hanna at the Weizmann Institute, Renewal Bio's co-founder and chief scientific advisor. The Hanna lab has published results in Nature , Cell , and Cell Stem Cell , growing mouse embryos outside the uterus and building mouse and human embryo models from stem cells. Renewal Bio holds an exclusive license to the platform.
Why now? The investment reflects Immortal Dragons' Replacement Strategy thesis, which holds that replacing aged or failing tissues is a direct path to extending healthy life. Cell supply is the limiting factor, and Renewal Bio is working to remove it.
"Cell supply is the bottleneck for replacement," said Boyang Wang, founder of Immortal Dragons. "Renewal Bio is taking it on with some of the most important science in the embryo-model field."
The signal: Immortal Dragons backs more than 15 portfolio companies and pairs investment with longevity advocacy through publishing and podcasts. Its bet on Renewal Bio signals growing investor appetite for regenerative platforms that aim to make replacement cells at scale.
Read more: pr-inside.com
Image credit: Tareq Salahuddin
